Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alfa-2a for severe fever with thrombocytopenia syndrome
ChiCTR-IPR-15006285Phase 4Recruiting
- Sponsor
- Beijing Institute of Microbiology and Epidemiology
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of interferon alfa-2a in severe fever with thrombocytopenia syndrome (SFTS) (2 arms), sponsored by Beijing Institute of Microbiology and Epidemiology. Primary endpoints: Case fatality rate of severe fever with thrombocytopenia syndrome and Viral load clearance rate of severe fever with thrombocytopenia syndrome virus. Started Apr 2015; status: recruiting.
02
Drugs
interferon alfa-2a
03
Conditions
severe fever with thrombocytopenia syndrome (SFTS)
Beyond the preview
Go deeper on ChiCTR-IPR-15006285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006285.